华东医药：子公司获注射用HDM2020临床试验批准

Core Viewpoint - The approval of clinical trials for HDM2020 marks a significant milestone in the development of a new targeted antibody-drug conjugate aimed at treating advanced solid tumors, enhancing the company's competitiveness in the oncology treatment sector [1] Company Summary - Huadong Medicine's wholly-owned subsidiary, Sino-American Huadong, received the Clinical Trial Approval Notice from the National Medical Products Administration for HDM2020 [1] - HDM2020 targets fibroblast growth factor receptor 2b and has demonstrated significant anti-tumor activity in preclinical studies [1] - The company plans to continue advancing drug development and will disclose information based on progress [1] Industry Summary - The approval of HDM2020 for clinical trials reflects ongoing innovation in the oncology treatment field, particularly in the development of targeted therapies [1] - The successful development and potential commercialization of HDM2020 could position the company favorably within the competitive landscape of cancer therapeutics [1]